Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at CooperCompanies (NASDAQ: COO) and the best and worst performers in the medical devices & supplies - diversified industry.

The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies. However, the capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers.

The 6 medical devices & supplies - diversified stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 0.6% while next quarter’s revenue guidance was in line.

In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results.

CooperCompanies (NASDAQ: COO)

With a history dating back to 1958 and a portfolio spanning two distinct healthcare segments, Cooper Companies (NASDAQ: COO) develops and manufactures medical devices focused on vision care through contact lenses and women's health including fertility products and services.

CooperCompanies reported revenues of $1.07 billion, up 4.6% year on year. This print was in line with analysts’ expectations, and overall, it was a strong quarter for the company with a solid beat of analysts’ full-year EPS guidance estimates and an impressive beat of analysts’ EPS guidance for next quarter estimates.

"We closed fiscal 2025 ahead of consensus revenue, earnings, and free cash flow expectations, and we enter 2026 with clear priorities to drive long-term shareholder value: accelerating top-line growth, improving profitability, accelerating cash generation, and continuing share repurchases," said Al White, CooperCompanies' President and CEO.

CooperCompanies delivered the weakest full-year guidance update of the whole group. Interestingly, the stock is up 6.4% since reporting and currently trades at $81.96.

Is now the time to buy CooperCompanies? Access our full analysis of the earnings results here, it’s free for active Edge members.

Best Q3: Neogen (NASDAQ: NEOG)

Founded in 1981 and operating at the intersection of food safety and animal health, Neogen (NASDAQ: NEOG) develops and manufactures diagnostic tests and related products to detect dangerous substances in food and pharmaceuticals for animal health.

Neogen reported revenues of $209.2 million, down 3.6% year on year, outperforming analysts’ expectations by 2.6%. The business had a very strong quarter with an impressive beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.

Neogen achieved the biggest analyst estimates beat and highest full-year guidance raise among its peers. The market seems happy with the results as the stock is up 19.8% since reporting. It currently trades at $6.90.

Is now the time to buy Neogen? Access our full analysis of the earnings results here, it’s free for active Edge members.

Weakest Q3: Baxter (NYSE: BAX)

With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.

Baxter reported revenues of $2.84 billion, up 5% year on year, falling short of analysts’ expectations by 1.4%. It was a softer quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates and revenue guidance for next quarter missing analysts’ expectations significantly.

Baxter delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 14.8% since the results and currently trades at $19.11.

Read our full analysis of Baxter’s results here.

Boston Scientific (NYSE: BSX)

Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.

Boston Scientific reported revenues of $5.07 billion, up 20.3% year on year. This print topped analysts’ expectations by 1.9%. It was a very strong quarter as it also recorded an impressive beat of analysts’ organic revenue estimates and revenue guidance for next quarter topping analysts’ expectations.

Boston Scientific delivered the fastest revenue growth among its peers. The stock is down 4.3% since reporting and currently trades at $95.60.

Read our full, actionable report on Boston Scientific here, it’s free for active Edge members.

Stryker (NYSE: SYK)

With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.

Stryker reported revenues of $6.06 billion, up 10.2% year on year. This result was in line with analysts’ expectations. Overall, it was a satisfactory quarter as it also logged organic revenue in line with analysts’ estimates.

The stock is down 4.8% since reporting and currently trades at $351.47.

Read our full, actionable report on Stryker here, it’s free for active Edge members.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.